Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2291]
News [4645]
Articles [192]
Editorials [8]
Conferences [136]
elearning [9]
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for...
Dr Silvia Novello - University of Turin, Turin, Italy
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
11 Sep 2022
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable...
Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022
Lenvatinib remains standard of care for first-line therapy in advanced...
Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma ( Prof Richard S Finn - UCLA Health Santa Monica Cancer Care, Santa Monica, USA )
11 Sep 2022
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022
Lasofoxifene shows promise for women with ESR1-mutated mBC
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...
Lasofoxifene shows promise for women with ESR1-mutated mBC ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022
New data presented at ESMO for multi-cancer early detection
Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences
New data presented at ESMO for multi-cancer early detection ( Dr Tom Beer - Vice President and Chief Medical Officer of Exact Sciences )
10 Sep 2022
Perioperative nivolumab did not improve RFS in RCC patients at high risk for...
Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA
Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence ( Dr Mohamad Allaf - The Johns Hopkins Hospital, Baltimore, USA )
10 Sep 2022
Nirogacestat demonstrates clinically significant improvement in PFS versus...
Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany
Nirogacestat demonstrates clinically significant improvement in PFS versus placebo for progressing desmoid tumours ( Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany )
10 Sep 2022
Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly...
Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands
Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma ( Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )
10 Sep 2022
WCLC 2022: Highlights
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
WCLC 2022: Highlights ( Dr Luis Raez - Memorial Cancer Institute, Florida, USA )
31 Aug 2022
Colorectal cancer and precision oncology
Dr Anguraj Sadanandam - The Institute of Cancer Research, London, UK
Colorectal cancer and precision oncology ( Dr Anguraj Sadanandam - The Institute of Cancer Research, London, UK )
22 Aug 2022
An overview of treatment advances in gastric cancer
Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA
An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )
18 Aug 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation